alexa Second-generation antipsychotic long-acting injections: systematic review.


Journal of Neuropsychopharmacology & Mental Health

Author(s): Fleischhacker WW

Abstract Share this page

Abstract BACKGROUND: Second-generation antipsychotics (SGAs) represent an advance in the long-term management of schizophrenia. AIMS: To review the available evidence concerning SGA long-acting injections (LAIs). METHOD: A systematic review of the literature was conducted using PubMed. RESULTS: Risperidone long-acting injection was the first licensed SGA-LAI compound and is effective in the long-term management of schizophrenia, with a safety profile similar to that of oral risperidone. Olanzapine pamoate has recently been approved in Europe. In terms of efficacy, at injection intervals of up to 4 weeks it appears comparable to oral olanzapine, although the potential for ;post-injection syndrome' (delirium) calls for additional safety considerations. Paliperidone palmitate is currently under review with the licensing authorities. It also affords the potential advantage of monthly dosing. CONCLUSIONS: More long-term comparisons of SGA-LAIs with oral SGAs as well as with first-generation antipsychotic LAIs are needed. These studies should include cost-effectiveness data. This article was published in Br J Psychiatry Suppl and referenced in Journal of Neuropsychopharmacology & Mental Health

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version